ArticleScientific reports2017
Constraint-based modeling identifies new putative targets to fight colistin-resistant A. baumannii infections.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Transcriptome-constrained genome-scale metabolic modeling reveals central carbon and amino acid metabolic reprogramming underlying colistin-sulbactam synergy inAntimicrobial agents and chemotherapy · 2026Article
- An integrative in silico and in vitro synergy of Cinnamomum verum essential oil and cinnamaldehyde with imipenem against extensively drug-resistant Gram-negative bacteria.Scientific reports · 2026Article
- Transcriptome-driven constraint-based modelling reveals metabolic targets for ovarian cancer.Cancer & metabolism · 2026Article
- Modelling reliable metabolic phenotypes by analysing the context-specific transcriptomics data.NPJ systems biology and applications · 2025Article
- An integrated systems biology approach establishes arginine biosynthesis as a metabolic weakness in Candida albicans during host infection.Cell communication and signaling : CCS · 2025Article
- Deciphering Antibiotic-Targeted Metabolic Pathways inLife (Basel, Switzerland) · 2024Article
- Exploring the metabolic profile of A. baumannii for antimicrobial development using genome-scale modeling.PLoS pathogens · 2024Article
- Genome-scale model ofMicrobiology spectrum · 2024Article
- Risk Factors Associated with Mortality inAntibiotics (Basel, Switzerland) · 2024Article
- Uses of Multi-Objective Flux Analysis for Optimization of Microbial Production of Secondary Metabolites.Microorganisms · 2023Review
- Understanding Antimicrobial Resistance Using Genome-Scale Metabolic Modeling.Antibiotics (Basel, Switzerland) · 2023Review
- Genome-scale metabolic modeling andFrontiers in cellular and infection microbiology · 2023Article
- Identification of fungus-growing termite-associated halogenated-PKS maduralactomycin a as a potential inhibitor of MurF protein of multidrug-resistantFrontiers in molecular biosciences · 2023Article
- Genome-scale metabolic modeling in antimicrobial pharmacology.Engineering microbiology · 2022Review
- Article
- Genome-Scale Metabolic Modelling Approach to Understand the Metabolism of the Opportunistic Human PathogenMetabolites · 2022Article
- Dual transcriptome based reconstruction of Salmonella-human integrated metabolic network to screen potential drug targets.PloS one · 2022Article
- Bacterial metabolism and pathogenesis intimate intertwining: time for metabolic modelling to come into action.Microbial biotechnology · 2022Article
- Modelling hCDKL5 Heterologous Expression in Bacteria.Metabolites · 2021Article
- Novel antimicrobial development using genome-scale metabolic model of Gram-negative pathogens: a review.The Journal of antibiotics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii is a clinical threat to human health, causing major infection outbreaks worldwide. As new drugs against Gram-negative bacteria do not seem to be forthcoming, and due to the microbial capability of acquiring multi-resistance, there is an urgent need for novel therapeutic targets. Here we have derived a list of new potential targets by means of metabolic reconstruction and modelling of A. baumannii ATCC 19606. By integrating constraint-based modelling with gene expression data, we simulated microbial growth in normal and stressful conditions (i.e. following antibiotic exposure). This allowed us to describe the metabolic reprogramming that occurs in this bacterium when treated with colistin (the currently adopted last-line treatment) and identify a set of genes that are primary targets for developing new drugs against A. baumannii, including colistin-resistant strains. It can be anticipated that the metabolic model presented herein will represent a solid and reliable resource for the future treatment of A. baumannii infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.